Your browser doesn't support javascript.
loading
Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: a promising approach for the treatment of defective telomerase disorders.
Egusquiaguirre, Susana P; Manguán-García, Cristina; Pintado-Berninches, Laura; Iarriccio, Laura; Carbajo, Daniel; Albericio, Fernando; Royo, Miriam; Pedraz, José Luís; Hernández, Rosa M; Perona, Rosario; Igartua, Manuela.
Affiliation
  • Egusquiaguirre SP; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.
  • Manguán-García C; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Madrid, Spain.
  • Pintado-Berninches L; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Madrid, Spain.
  • Iarriccio L; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Madrid, Spain; Advanced Medical Projects, Madrid, Spain.
  • Carbajo D; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain; Institut de Recerca Biomédica, Barcelona, Spain; Unitat de Química Combinatòria, Parc Científic de Barcelona, Barcelona, Spain.
  • Albericio F; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain; Institut de Recerca Biomédica, Barcelona, Spain.
  • Royo M; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain; Unitat de Química Combinatòria, Parc Científic de Barcelona, Barcelona, Spain.
  • Pedraz JL; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.
  • Hernández RM; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.
  • Perona R; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Madrid, Spain. Electronic address: rperona@iib.uam.es.
  • Igartua M; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain. Electronic address: manoli.igartua@ehu.es
Eur J Pharm Biopharm ; 91: 91-102, 2015 Apr.
Article in En | MEDLINE | ID: mdl-25660910
Subject(s)
Biocompatible Materials/chemistry; Cell Cycle Proteins/chemistry; Drug Delivery Systems; Enzyme Reactivators/chemistry; Nanoparticles/chemistry; Nuclear Proteins/chemistry; Peptide Fragments/chemistry; Animals; Biocompatible Materials/adverse effects; Biological Transport; Cell Cycle Proteins/administration & dosage; Cell Cycle Proteins/adverse effects; Cell Cycle Proteins/genetics; Cell Line; Cell Survival/drug effects; Cell-Penetrating Peptides/adverse effects; Cell-Penetrating Peptides/chemistry; Cells, Cultured; Chemical Phenomena; Delayed-Action Preparations/administration & dosage; Delayed-Action Preparations/adverse effects; Delayed-Action Preparations/chemistry; Delayed-Action Preparations/therapeutic use; Drug Compounding; Drug Delivery Systems/adverse effects; Drug Liberation; Drug Stability; Dyskeratosis Congenita/drug therapy; Enzyme Reactivators/administration & dosage; Enzyme Reactivators/adverse effects; Enzyme Reactivators/therapeutic use; Humans; Lactic Acid/adverse effects; Lactic Acid/chemistry; Mice; Nanoparticles/adverse effects; Nuclear Proteins/administration & dosage; Nuclear Proteins/adverse effects; Nuclear Proteins/genetics; Peptide Fragments/administration & dosage; Peptide Fragments/adverse effects; Peptide Fragments/genetics; Polyamines/adverse effects; Polyamines/chemistry; Polyelectrolytes; Polyethylene Glycols/adverse effects; Polyethylene Glycols/chemistry; Polyglactin 910/adverse effects; Polyglactin 910/chemistry; Polyglycolic Acid/adverse effects; Polyglycolic Acid/chemistry; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Stability; Recombinant Proteins/administration & dosage; Recombinant Proteins/adverse effects; Recombinant Proteins/chemistry; Recombinant Proteins/therapeutic use
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Biocompatible Materials / Nuclear Proteins / Drug Delivery Systems / Cell Cycle Proteins / Enzyme Reactivators / Nanoparticles Language: En Journal: Eur J Pharm Biopharm Journal subject: FARMACIA / FARMACOLOGIA Year: 2015 Document type: Article Affiliation country: Spain Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Biocompatible Materials / Nuclear Proteins / Drug Delivery Systems / Cell Cycle Proteins / Enzyme Reactivators / Nanoparticles Language: En Journal: Eur J Pharm Biopharm Journal subject: FARMACIA / FARMACOLOGIA Year: 2015 Document type: Article Affiliation country: Spain Country of publication: Netherlands